Woulgan

Enhances Macrophage Activity

Woulgan

Woulgan® Bioactive Beta-Glucan Gel is a treatment for both acute and chronic wounds where wound healing is slow, or is anticipated to heal slower than normal or is at high risk of becoming stalled. Woulgan® has a unique formulation with gel properties and beta-glucan which reactivates stalled healing and accelerates the healing process[1,2].

 

Product benefits

  • Provides an optimal moist wound-healing environment
  • Re-hydrates necrotic tissue
  • Aids in autolytic debridement
  • Promotes angiogenesis, cell proliferation and wound contraction

References
[1] www.clinicaltrials.gov ID number: NCT 00288392, https://woulgan.com/about/science-behind-woulgan/.
[2] Five model studies using Woulgan in wound healing in diabetic mice. Studies performed by a contract research laboratory for Biotec
BetaGlucans.

Woulgan® clinical studies

Author(s) Title Publication
Wilde, K. Use of Woulgan in neuropathic and vascular complex wounds Wounds UK, 2019, poster View
Woulgan Made Easy Wounds UK, 2018, 14(5) View
Hunt, S,D. A clinical observation evaluation of bioactive soluble beta-glucan gel compared with standard care Journal of Wound Care, 2018, 27(9) View
Cutting, K. Health economics of a bioactive beta-glucan gel Wounds UK, 2016, poster View
Cutting, K. The nature of beta-glucans – and the role in wound care of a novel bioactive beta-glucan gel: Woulgan Wounds UK, 2016, poster View
Fitzgerald, R. The clinical and patient experience of using a bioactive beta-glucan gel on a hard-to-heal wound Wounds UK, 2016, poster View
Hepworth, L. Two case studies to demonstrate the use of an innovative bioactive beta-glucan product for the treatment of stalled wounds Wounds UK, 2016, poster View
King, B., Barrett, S. and Cutting, K.F. Clinical evaluation of a bioactive beta-glucan gel in the treatment of ‘hard-to-heal’ wounds Journal of Wound Care, 2017, 26(2) View
Overfield, J. The use of Woulgan to heal a chronic leg ulceration Wounds UK, 2016, poster View
Svetlana, N. Zykova, et al.

Macrophage stimulating agent soluble yeast β-1,3/1,6-glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo-controlled phase II study

Journal of Diabetes Investigation, 2014, 5(4) View
Welch, D. A clinical evaluation of Woulgan Biogel in the management of non-infected diabetic foot ulcerations The Diabetic Foot Journal, 2017, 20(1)  View
Welch, D. A clinical evaluation of Woulgan in the management of non infected diabetic foot ulcerations Wounds UK, 2016, poster View
Woodrow, T. Successful use of an immunomodulator, Bioactive βeta-glucans, to progress a diabetic foot open amputation wound to final closure post negative pressure wound therapy: A case study. Wound Care Today, 2019, Poster View


References
[1] www.clinicaltrials.gov ID number: NCT 00288392, https://woulgan.com/about/science-behind-woulgan/.3091 WCT Woulgan abstract poster_v2d
[2] Five model studies using Woulgan in wound healing in diabetic mice. Studies performed by a contract research laboratory for Biotec
BetaGlucans.

Woulgan® is indicated for use in stalled, dry or low to medium-exuding partial- or full-thickness wounds:

  • Diabetic foot uclers
  • Leg ulcers (any aetiology)
  • Pressure ulcers
  • Graft and donor sites
  • Open surgical wounds
  • Partial-thickness burns
  • Abrasions and lacerations

Is the wound healing too slow? Try using the wound calculator and find out!

 

References
[1] www.clinicaltrials.gov ID number: NCT 00288392, https://woulgan.com/about/science-behind-woulgan/.
[2] Five model studies using Woulgan in wound healing in diabetic mice. Studies performed by a contract research laboratory for Biotec
BetaGlucans.

Applying Woulgan®*

Woulgan® should be applied to a prepared wound bed twice weekly and covered with a suitable secondary dressing.

  • Cleanse wound according to local protocol
  • Debride if required
  • If required protect the wound edges
  • Cover the wound surface with a thin layer of Woulgan®
  • Apply a suitable secondary dressing of choice and fixate
  • Apply compression or offloading if indicated

You can view the full user guide here 

View our how to apply video below;

 

*See product insert leaflet for full instructions for use.


References
[1] www.clinicaltrials.gov ID number: NCT 00288392, https://woulgan.com/about/science-behind-woulgan/.
[2] Five model studies using Woulgan in wound healing in diabetic mice. Studies performed by a contract research laboratory for Biotec
BetaGlucans.

Item Size Pieces per box Product code PIP code NHS code
Woulgan® 4g 4 WGA04EA001 406-4192 ELZ867

 

References
[1] www.clinicaltrials.gov ID number: NCT 00288392, https://woulgan.com/about/science-behind-woulgan/.
[2] Five model studies using Woulgan in wound healing in diabetic mice. Studies performed by a contract research laboratory for Biotec
BetaGlucans.